We are delighted to be exhibiting again at AUA,
Come and meet us at Booth #765. Hear about new developments.
Register for samples.
The FLUME® catheter is 510(k) cleared in the U.S. for both urethral and suprapubic indications.
New VP Engineering overseeing strategic manufacturing transfer
Kristian Olsen has joined as VP Engineering. Kristian has worked with us since 2019 as the senior project engineer at Biomerics. He has been instrumental in the development of our current device and all the manufacturing processes. We are delighted that Kristian is coming on board and brings a wealth of experience in balloon catheter development. His first task if to oversee the transfer of current production to a leading global contract catheter manufacturer with whom we have signed a supply agreement. We are excited at the prospect of having the support of their capabilities as we look to scale up high quality and efficient production.
Research Study on Comfort of the New FLUME Catheter to Begin Recruitment
Duke Clinical Research Institute and Penn State College of Medicine Partner to Collect Patient Insight on Innovative FLUME Catheter
The Flume Catheter Company Ltd. (TFCC), a medical device company dedicated to developing an improved alternative to the Foley indwelling urinary catheter, announced the launch of a study to gather real-world data on patient experiences with the new FLUME catheter.
AUA 2023, Chicago, April 28-May 1
We are delighted to be exhibiting in the ‘Emerging Corner’ at AUA, aimed at showcasing new innovations in urology.
Come and meet us at Booth #1029
Learn more about our studies to evaluate FLUME vs Foley on
Patient comfort and Quality of Life
the incidence and costs of CAUTI and other complications.
Register for samples
The FLUME catheter is 510(k) cleared in the U.S.
DEVICE ALLIANCE - PODCAST 52
Roger Holmes, Co-Founder & CEO of The Flume Catheter Company Inc. was honored to participate in Medtech Radio’s DeviceAlliance latest podcast.. He and host Scott Johnson discuss.. - The catheter problem impacting 100M people - The 2.2B burden in the U.S. - FLUME Catheter's goal to impact millions for a philanthropic purpose - Roger's life lessons in entrepreneurship
Presenting at McKinsey ESIC conference
We were delighted to be selected as one of just 10 Medtech startups to pitch during the McKinsey ESIC (Early Stage Investors Conference). An opportunity to present to a very relevant audience and also to a panel of experts that shared their observations and questions.
FLUME catheter on AUA TV in New Orleans
FLUME founders Dr. John Havard and Roger Holmes being interviewed by AUA TV for the Emerging Corner at AUA 22 in New Orleans.
FLUME catheter successfully raises £2.1m Angel II funding round
The Flume Catheter Company has successfully completed its second Angel funding round, that was oversubscribed at £2.1m ($2.8m). This will be used to initiate a controlled market release in the US in 2022 and to build the platform for a wider commercial launch in 2023. As a key part of this, Duke Clinical Research Institute have been commissioned to design and oversee the gathering of comparative patient data for FLUME vs Foley in the US. This is in addition to the NIHR funded ‘Research for Patient Benefit’ evaluation that is underway in Bristol in the UK.
First patient - Research for Patient Benefit (RfPB) Study in UK
Tweet today by Chief Investigator Prof. Marcus Drake on first patient for NIHR funded Research for Patient Benefit (RfPB) Study. With thanks to all the Bristol team. Follow Prof. Drake below
Introducing FLUME at AUA 2022
The FLUME catheter will launch at AUA 2022 in New Orleans, the largest annual meeting of urologists globally. FLUME will be in Booth 2479 in the “Emerging Corner”, an area showcasing new innovations. Come and meet founders Dr. John Havard and Roger Holmes and have the opportunity to see and discuss the innovative FLUME catheter.
The company is conducting a controlled market release in 2022 and is keen to align with partners who have a track record of innovation in patient care. For those interested in FLUME as an option for their patients, there will be the opportunity to request sample devices to support formulary listings.
The FLUME catheter is 510(k) cleared and is manufactured in the United States.
We look forward to meeting you at AUA!